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Abstract
Background: Gastrointestinal illness is a major cause of morbidity in travellers and is a common reason for
presentation to healthcare services on return. Whilst the aetiology of imported gastrointestinal disease is
predominantly infectious, outcomes are variable due to a range of phenomena such as post-infectious irritable
bowel syndrome, drug resistance and occult pathology (both infectious and non-infectious). Previous studies have
focussed on predictors of aetiology of gastrointestinal disease in travellers; we present a retrospective study
combining both aetiological and early outcome data in a large cohort of returned travellers.
Method: We identified 1450 patients who attended our post-travel walk-in clinic with gastrointestinal
symptoms between 2010 and 2016. Demographic, travel, clinical and laboratory data was collected through
case note review. Logistic regression analysis to examine correlates of aetiology and outcome were performed
in R (CRAN Project 2017).
Results: Of 1450 patients in our cohort 153 reported bloody diarrhoea and 1081 (74.6%) reported non-bloody
diarrhoea. A definitive microbiological diagnosis was made in 310 (20.8%) of which 137 (9.4%) had a parasite
identified and 111 (7.7%) had a bacterial cause identified. Factors associated with a parasitological diagnosis
included history of travel to South Asia (aOR = 2.55; 95%CI 1.75–3.70, p < 0.0001) and absence of bloody
diarrhoea (aOR = 0.22; 95%CI 0.066–0.53, p < 0.005). Factors associated with a bacteriological diagnosis included
male gender (aOR = 1.69; 95%CI 1.10–2.62, p < 0.05), an age < 37 years on presentation (aOR = 2.04; 95%CI 1.25–
3.43, p < 0.01), white cells on stool microscopy (aOR = 3.52; 95%CI 2.09–5.86, p < 0.0001) and a C-reactive
protein level of >5iu/dL (aOR = 4.68; 95%CI 2.91–7.72, p < 0.0001). The majority (1235/1450, 82.6%) reported full
symptomatic resolution by the first follow up visit; factors associated with lack of symptomatic resolution
included female gender (aOR = 1.45 95%CI 1.06–1.99, p < 0.05), dysenteric diarrhoea (aOR = 2.14 (95%CI 1.38–
3.25, p < 0.0005) and elevated peripheral leukocyte count (aOR = 1.58 95%CI 1.02–2.40, p < 0.05).
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Conclusions: In a cohort of returned travellers, we were able to identify multiple factors that are correlated
with both aetiology and outcome of imported gastrointestinal syndromes. We predict these data will be
valuable in the development of diagnostic and therapeutic pathways for patients with imported
gastrointestinal infections.
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Key points
Gastrointestinal pathology is common in returned trav-
ellers. In this large retrospective study, we identify a
number of demographic, clinical and laboratory features
which are associated with the aetiology and clinical out-
come of imported enteric diseases.
Introduction
Diarrhoea and other gastrointestinal diseases are ex-
tremely common in travellers and remain a key cause of
morbidity in this group despite reports of reducing inci-
dence of foodborne infection worldwide [1–4]. Multiple
studies including large-scale GeoSentinel analyses have
estimated between 20 and 50% of travellers experience
gastrointestinal symptoms related to travel; this risk is
enhanced in lower- and middle-income countries with
up to 40,000 travellers to these destinations experiencing
symptoms per day [5–9]. Imported gastrointestinal dis-
ease represents a spectrum of different clinical syn-
dromes of which acute diarrhoeal illness is the most
common, accounting for 60% or more of all presenta-
tions to medical care on return [1, 5, 6].
The aetiology of imported gastrointestinal pathology is
predominantly infectious in nature and microbiological
identification of the causative agent is successful in be-
tween 20 and 94% of patients with acute diarrhoeal ill-
ness [1, 5, 10]. Most cases of imported diarrhoea are
bacterial in origin [1]. However, in a large GeoSentinel
study, in the 39% of returning travellers with any gastro-
intestinal syndrome who received a microbiological diag-
nosis, approximately twice as many had a parasite
identified (65%) as those who had a bacterial cause iso-
lated (31%) [6]. A previous report from our centre iden-
tified a bacterial origin for symptoms in 12.5% and a
parasitic cause in 11.9% of patients with acute diarrhoea
[11]. Bacterial causes of acute diarrhoea typically have a
shorter incubation and duration than those of parasitic
origin, and this may explain previous reported disparities
in comparative aetiological prevalence [9, 11]. Identifica-
tion of factors which predict aetiology of imported
gastrointestinal disturbance are therefore of interest as
they may help guide empirical therapy, prognosis and
follow up [1, 9, 11] Limited work has previously been
done in this arena; in this work we seek to extend and
strengthen these earlier observations [11].
The majority of infective gastrointestinal disease, and
particularly diarrhoeal illness, is short-lived and self-
limiting, with an average duration of 4–5 days [12].
However, long term complications are well-recognised
of which post-infectious irritable bowel syndrome (PI-
IBS), characterised by a persistence in gastrointestinal
distress after convalescence, is best described and occurs
in nearly 1 in 5 patients [13, 14]. Persistence of symp-
toms after less common imported gastrointestinal syn-
dromes such as isolated abdominal pain or bloating are
less well described. Precipitators of non-resolution of
symptoms after treatment for an acute imported gastro-
intestinal infection can be broadly divided into five cat-
egories: resistance of pathogen to empirical treatment,
failure of host response (e.g. immunocompromise), cryp-
tic infection, primary non-infectious pathology (such as
undiagnosed inflammatory bowel disease) and, func-
tional post-infectious bowel abnormalities, of which PI-
IBS is the most well described [13–19]. As functional
bowel disease is a diagnosis of exclusion, the initial
evaluation of patients with recalcitrant gastrointestinal
symptoms usually necessitates further laboratory and
imaging investigations and may include invasive assess-
ments such as endoscopy [1].
Early identification and effective treatment of travellers
with persistent gastrointestinal symptoms is clinically
challenging. Despite this, only a limited number of stud-
ies have directly looked at predictive factors for non-




The Hospital for Tropical Diseases (London, UK) oper-
ates a Walk-in Emergency clinic for any patient with
symptoms following return from abroad. Patients self-
refer and do not need a prior appointment or review by
their primary healthcare practitioner before review. In
order to be eligible for review patients must have
returned from travel within the preceding 6 months. The
clinic target population is adult travellers however older
adolescents > 16 years are occasionally reviewed at clin-
ician discretion. Other than this there are no pre-
requisites for review. Each patient is assessed by a triage
nurse and subsequently by a doctor, where an initial
diagnosis is made, and emergency treatment is provided.
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A subset of these patients will return to clinic either as a
planned follow-up or re-present due to symptom persist-
ence. Patients routinely receive a call from a clinician
within 7 days with the results of investigations per-
formed at the time of review, at this time a brief update
on symptoms is sought by the telephoning clinician; this
process is independent of otherwise planned follow-up.
Cohort selection
All patients with gastrointestinal symptoms presenting
to the Hospital for Tropical Diseases Emergency Walk-
in Clinic (London, UK) have a stool sample requested
for analysis for ova, cysts and parasites (OCP) at triage.
We identified stool samples submitted for stool OCP to
the Hospital for Tropical Diseases Parasitology Depart-
ment between January 2010 and January 2016. From this
we identified patient-episodes corresponding to individ-
ual attendances at the clinic. Patients were deemed ineli-
gible for analysis if they provided samples for
asymptomatic screening for parasites in the context of
another, non-gastrointestinal, illness and if the sample
was derived from the parallel tertiary referral outpatient
clinic which operates on the same site. This is due to the
fact that other clinics operating on the same site do not
restrict their patient population to recently returned
travellers.
Syndromic categorisation and outcome parameters
Patients were grouped into syndromic categories as de-
scribed in Fig. 1. Presence of the first indicator symptom
as detailed in the flow chart led to inclusion in that cat-
egory irrespective of other symptoms. This allowed de-
lineation of potentially overlapping gastrointestinal
symptom clusters; for example, a patient with both dys-
enteric diarrhoea and abdominal pain would be cate-
gorised according to the higher ranked symptom
(dysenteric diarrhoea) for the purposes of syndrome
grouping for analysis.
The primary assessed outcome was complete reso-
lution of symptoms. This did not require only the reso-
lution of the highest graded symptom, but the absence
of any significant symptoms as reported by the patient.
For example, a patient in Group 1 (dysenteric diarrhoea)
at first presentation would be categorised as “Syndromic
non-resolution” if they had persistent non-bloody diar-
rhoea at the time of review.
Data collection
Routine data were collected via audit of historical clin-
ical records by clinical staff and anonymised before entry
onto a database. Scope of data included demographic de-
tails, clinical data from correspondence and laboratory
data from electronic records. All data were collected in
Fig. 1 Cohort Identification Methodology and Hierarchical Syndromic Grouping
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compliance with locally established audit standards and
personal data were anonymised in compliance with
GDPR legislation (European Union 2018).
Ethics and governance
All methods and protocols employed within this study
were approved by the Hospital for Tropical Diseases
Audit Committee (London, UK) in accordance with le-
gislation and regulations laid out by the NHS Human
Research Authority (UK).
Data analysis
Data were analysed in Microsoft Excel (Microsoft Cor-
poration 2018) and R (R Development Core Team,
2008). Students’ t-test was used for normally distributed
continuous variables, 2 by 2 tables were analysed using
Chi squared or Fisher’s Exact Test. Logistic regression
modelling was performed with binomial distribution pa-
rameters. Adjustment was made for major confounders
including age and gender and suspected interacting vari-
ables identified through univariate analysis. Further de-
tails and code used for analysis may be found on github.
com/rlever/HTDgastro. Maps were produced with the




From 3851 stool samples submitted for stool OCP ana-
lysis, we identified 1450 consecutive patients who had
attended the Emergency Walk-in clinic between January
2010 and January 2016 who had a primary gastrointes-
tinal syndrome after return from abroad. 819 patients
(56.5%) were female, and the mean age was 35.97 years
(IQR 27.3–42.4 years). 445 (30.1%) of reviewed patients
had visited more than one country during their trip and
430 (29.7%) had visited more than one geographical re-
gion of the world. The top geographical regions visited
were South East Asia (449/1450 31.0%), South Asia
(356/1450 24.6%) and East Africa (323/1450 22.3%).
(Table 1.; Fig. 2.)
Syndromic presentations of gastrointestinal disease
Imported gastrointestinal disease encompasses a
spectrum of clinical presentations; to capture this in a
clinician applicable manner we separated patients into 4
syndromic categories. Group 1: Dysenteric diarrhoea
(defined as a diarrhoeal illness with the presence of
blood in the stool); Group 2: Non-dysenteric diarrhoea
(defined as any diarrhoeal illness without the presence of
blood); Group 3: Abdominal pain/Bloating (defined as
the presence of abdominal pain and/or bloating without
diarrhoea); Group 4: Other (defined as all other gastro-
intestinal syndromes not captured in Groups 1–3).
Group 4 included those who reported isolated nausea or
vomiting, passage of a suspected helminth in stool, sus-
pected helminth in emesis, altered bowel habit without
diarrhoea, pruritis ani, constipation, and oral ulceration.
The commonest syndrome in our cohort was Non-
dysenteric diarrhoea (1081 patients, 74.6%) followed by
Abdominal pain/Bloating (176 patients, 12.1%) and Dys-
enteric diarrhoea (153 patients, 10.6%) (Fig. 1.).
Laboratory investigation of patients presenting to the
walk-in clinic
All our patients had microscopy performed on a stool
concentrate for ova, cysts and parasites. In addition,
90.7% of patients underwent bacterial stool culture and
42.1% had molecular analysis for Entamoeba histolytica,
Giardia intestinalis and Cryptosporidium performed via
multiplex polymerase chain reaction. Peripheral blood
sampling was performed in the majority of patients –
95.1% had full blood count (FBC), 94.7% had C-reactive
protein and 94.8% had liver function tests performed re-
spectively. 43.8% underwent testing for HIV infection.
Aetiology of gastrointestinal disease in returning
Travellers
301 patients (20.8%) received a definitive diagnosis as a
result of their interaction with our travellers’ clinic of
which 242 (80.3%) were as a result of microbiological
and parasitological analysis of stool.
The presence of a parasite was confirmed in 137 pa-
tients (9.4%) and a bacterial pathogen was identified in
111 patients (7.7%). The commonest identified gastro-
intestinal pathogen in our cohort was Giardia intestina-
lis which was identified in 92 patients (6.3%). The
commonest causes of bacterial gut infection were Sal-
monella spp. (39 cases, 2.7%) and Campylobacter spp.
(47 cases, 3.2%).
Patients in whom a parasite was identified were more
likely to fall into syndromic Group 2 (non-dysenteric
diarrhoea) (Table 1). Of note 6 of 7 E.histolytica infec-
tions identified by PCR presented with non-dysenteric
diarrhoea. Reported travel to South Asia was associated
with an increased risk for detection of a parasite during
clinical workup (aOR = 2.55; 95%CI 1.75–3.70, p <
0.0001) and particularly for Giardia intestinalis infection
(aOR = 3.18; 95% CI = 2.05–4.92, p < 0.00001); corres-
pondingly, those who reported dysenteric diarrhoea were
significantly less likely to have a parasite identified dur-
ing testing (aOR = 0.22; 95%CI 0.066–0.53, p < 0.005)
(Table 2).
Patients with a proven bacterial origin to their symp-
toms had a younger mean age (33.3 vs 36.0 years, p =
0.016) and were more likely to fall into syndromic
Group 1 (dysenteric diarrhoea) (Table 1) After adjust-
ment for confounders male gender was significantly
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Table 1 Clinical Characteristics – Parasitic and Bacterial Diagnosis
Any Parasitic Diagnosis (N = 137) p value Any Bacterial Diagnosis (N = 111) p value Total (N = 1450)
Gender 0.802 *0.006
Female 76 (55.5%) 49 (44.1%) 819 (56.5%)
Male 61 (44.5%) 62 (55.9%) 631 (43.5%)
Age 0.276 *0.018
Mean (SD) 37.065 (12.685) 33.302 (11.987) 35.971 (12.353)
Range 16.720 - 73.200 16.930 - 73.200 15.240 - 84.540
HIV Positive 0 (0.0%) 0.901 0 (0.0%) 0.811 2 (0.1%)
Travel History
Central Asia 6 (4.4%) 0.176 2 (1.8%) 0.574 38 (2.6%)
Europe 3 (2.2%) 0.337 2 (1.8%) 0.279 53 (3.7%)
North Africa 11 (8.0%) 0.151 14 (12.6%) 0.781 171 (11.8%)
Pacific Islands 0 (0.0%) 0.518 1 (0.9%) 0.191 4 (0.3%)
Southern Africa 5 (3.6%) 0.165 2 (1.8%) *0.039 93 (6.4%)
Caribbean 1 (0.7%) 0.038 4 (3.6%) 0.796 59 (4.1%)
South America 14 (10.2%) 0.484 8 (7.2%) 0.581 125 (8.6%)
Australia and New Zealand 2 (1.5%) 0.901 2 (1.8%) 0.85 23 (1.6%)
Bahamas 0 (0.0%) 0.575 0 (0.0%) 0.618 3 (0.2%)
Middle East 1 (0.7%) 0.12 1 (0.9%) 0.203 41 (2.8%)
South Asia 54 (39.4%) < 0.001 14 (12.6%) *0.013 319 (22.0%)
Central America 8 (5.8%) 0.676 6 (5.4%) 0.573 97 (6.7%)
West Africa 13 (9.5%) 0.527 7 (6.3%) 0.094 161 (11.1%)
South East Asia 24 (17.5%) 0.433 31 (27.9%) *0.031 291 (20.1%)
East Africa 21 (15.3%) 0.404 26 (23.4%) 0.116 260 (17.9%)
North America and Canada 1 (0.7%) 0.264 3 (2.7%) 0.582 29 (2.0%)
Central Africa 3 (2.2%) 0.766 1 (0.9%) 0.436 27 (1.9%)
China 1 (0.7%) 0.145 2 (1.8%) 0.574 38 (2.6%)
Oceania 0 (0.0%) 0.428 1 (0.9%) 0.405 6 (0.4%)
Syndrome *0.008 < 0.001
Non-dysenteric diarrhoea 117 (85.4%) 81 (73.0%) 1081 (74.6%)
Abdominal pain 13 (9.5%) 3 (2.7%) 176 (12.1%)
Dysenteric diarrhoea 4 (2.9%) 25 (22.5%) 153 (10.6%)
Other 3 (2.2%) 2 (1.8%) 40 (2.8%)
Stool Microscopy
White cells 13 (9.5%) 0.751 36 (32.4%) < 0.001 127 (8.8%)
Red cells 8 (5.8%) 0.342 18 (16.2%) < 0.001 62 (4.3%)
Peripheral WBC Count 0.066 0.334
Decreased 1 (0.7%) 0 (0.0%) 14 (1.0%)
Increased 23 (16.8%) 15 (13.5%) 159 (11.0%)
Normal 110 (80.3%) 88 (79.3%) 1206 (83.2%)
C-reactive Protein 0.151 < 0.001
Increased 44 (32.1%) 77 (69.4%) 500 (34.5%)
Normal 90 (65.7%) 26 (23.4%) 873 (60.2%)
ALT 0.134 0.588
Increased 25 (18.2%) 14 (12.6%) 197 (13.6%)
Normal 108 (78.8%) 89 (80.2%) 1178 (81.2%)
Significance indicated by p value marked in bold with * where ≤0.001 < p < 0.05
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associated with a confirmed bacterial aetiology
(aOR = 1.69; 95%CI 1.10–2.62, p < 0.05), an age < 37
years on presentation (aOR = 2.04; 95%CI 1.25–3.43,
p < 0.01), presence of white cells on stool microscopy
(aOR = 3.52; 95%CI 2.09–5.86, p < 0.0001) and a C-
reactive protein level of >5iu/dL (aOR = 4.68; 95%CI
2.91–7.72, p < 0.0001) (Table 2). These data are con-
sistent with previously published observations from
our unit [11].
Outcomes of gastrointestinal disease in returning
Travellers
Persistent abdominal symptoms are a common feature
of returning travellers suffering from gastrointestinal
pathology. To assess the prevalence of persistent non-
resolution of symptoms within our cohort we identified
the patients who had any ongoing symptoms, either at
follow up after empirical treatment or the first follow up
after a specific identified aetiology was identified. Those
who failed to attend a pre-arranged follow up appoint-
ment were assumed to have syndromic resolution.
Of 1450 returning travellers, 215 (17.4%) had non-
resolution of their symptoms at follow up; the compara-
tive travel histories are shown in Fig. 2. A higher propor-
tion of patients with persistent symptoms compared to
those with complete resolution were female (62.8% vs
55.4%) and were more likely to have travelled to the
Caribbean, Pacific Islands, Bahamas and North America
respectively in a univariate analysis (Table 3). Dysenteric
diarrhoea as a presenting syndrome was over-
represented in those with persistent symptoms at follow
up (17.2% vs 9.4% of cases) however the presence of red
or white blood cells on stool microscopy was not signifi-
cantly different between the two groups (Table 3). No
individual microbiological or parasitological diagnosis
was associated with non-resolution of symptoms (Table
3). These findings may be related to new presentations
of non-travel related pathology such as inflammatory
bowel disease in these patients as has been previously
described by our centre [20].
In a multivariate analysis female gender was associated
with an hazard ratio of 1.45 (95%CI 1.06–1.99, p < 0.05)
for persistence of symptoms in our cohort (Table 4). An
initial presenting complaint of dysenteric diarrhoea, and
those with a measured peripheral leucocytosis at presen-
tation were associated with an hazard ratio of 2.14
(95%CI 1.38–3.25, p < 0.0005) and 1.58 (95%CI 1.02–
2.40, p < 0.05) respectively for non-resolution of symp-
toms (Table 4). Additionally, after adjustment for other
factors, travel to North America (USA and Canada) was
significantly associated with ongoing symptoms at follow-
up (HR 3.61, 95%CI 1.57–7.9, p < 0.005) (Table 4).
Discussion
To our knowledge this is the largest contemporary study
which focusses both on the aetiology and the outcomes
of returning travellers with gastrointestinal symptoms.
The results of this work therefore provide valuable data
to inform both empirical treatment of imported gastro-
intestinal disease and facilitate the early identification of
those patients who may have recalcitrant symptoms pos-
sibly due to non-infective causes and require follow-up.
Consistent with previous reports, our study demon-
strates that despite extensive investigation, only a
Fig. 2 Patient Travel Destination Circle size indicates number of patients as referenced in left-hand scale. Light green segments indicate
proportion of patients without syndromic resolution at follow-up
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Table 2 Predictors of Aetiology of Imported Gastrointestinal Disease
Resolution (N = 1235) Non-resolution (N = 215) Total (N = 1450) p value
Gender 0.043
Female 684 (55.4%) 135 (62.8%) 819 (56.5%)
Male 551 (44.6%) 80 (37.2%) 631 (43.5%)
Age 0.914
Mean (SD) 35.986 (12.241) 35.888 (13.009) 35.971 (12.353)
Range 16.000 - 84.540 15.240 - 78.340 15.240 - 84.540
Travel History
Central Asia 31 (2.5%) 7 (3.3%) 38 (2.6%) 0.528
Europe 46 (3.7%) 7 (3.3%) 53 (3.7%) 0.735
North Africa 144 (11.7%) 27 (12.6%) 171 (11.8%) 0.706
Pacific Islands 2 (0.2%) 2 (0.9%) 4 (0.3%) 0.047
Southern Africa 84 (6.8%) 9 (4.2%) 93 (6.4%) 0.149
Caribbean 44 (3.6%) 15 (7.0%) 59 (4.1%) 0.019
South America 108 (8.7%) 17 (7.9%) 125 (8.6%) 0.686
Bahamas 1 (0.1%) 2 (0.9%) 3 (0.2%) 0.011
Middle East 32 (2.6%) 9 (4.2%) 41 (2.8%) 0.193
Australia and New Zealand 19 (1.5%) 4 (1.9%) 23 (1.6%) 0.727
South Asia 264 (21.4%) 55 (25.6%) 319 (22.0%) 0.17
Central America 79 (6.4%) 18 (8.4%) 97 (6.7%) 0.285
West Africa 144 (11.7%) 17 (7.9%) 161 (11.1%) 0.106
South East Asia 248 (20.1%) 43 (20.0%) 291 (20.1%) 0.978
East Africa 227 (18.4%) 33 (15.3%) 260 (17.9%) 0.285
North America and Canada 19 (1.5%) 10 (4.7%) 29 (2.0%) 0.003
China 32 (2.6%) 6 (2.8%) 38 (2.6%) 0.866
Oceania 6 (0.5%) 0 (0.0%) 6 (0.4%) 0.306
Central.Africa 22 (1.8%) 5 (2.3%) 27 (1.9%) 0.586
Syndrome 0.002
Non-dysenteric diarrhoea 936 (75.8%) 145 (67.4%) 1081 (74.6%)
Abdominal pain 146 (11.8%) 30 (14.0%) 176 (12.1%)
Dysenteric diarrhoea 116 (9.4%) 37 (17.2%) 153 (10.6%)
Other 37 (3.0%) 3 (1.4%) 40 (2.8%)
Stool Microscopy
White cells 108 (8.7%) 19 (8.8%) 127 (8.8%) 0.965
Red cells 51 (4.1%) 11 (5.1%) 62 (4.3%) 0.509
Peripheral WBC Count 0.251
Decreased 12 (1.0%) 2 (0.9%) 14 (1.0%)
Increased 127 (10.3%) 32 (14.9%) 159 (11.0%)
Normal 1034 (83.7%) 172 (80.0%) 1206 (83.2%)
C-reactive Protein 0.209
Increased 435 (35.2%) 65 (30.2%) 500 (34.5%)
Normal 732 (59.3%) 141 (65.6%) 873 (60.2%)
ALT 0.447
Increased 164 (13.3%) 33 (15.3%) 197 (13.6%)
Normal 1004 (81.3%) 174 (80.9%) 1178 (81.2%)
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minority of patients with imported gastrointestinal dis-
turbance receive a microbiological diagnosis but that the
majority resolve completely with conservative, empirical,
or targeted management.
In agreement with a smaller earlier report from our
unit, travel to South Asia was associated with a positive
parasitological diagnosis, of which infection with Giardia
intestinalis was by far the most common. Similarly, the
identification of a causative bacterial agent was associ-
ated with dysenteric symptoms, white cells on stool mi-
croscopy and an elevated C-reactive protein level, in
accordance with the existing literature. Interestingly
younger age and male gender were significantly associ-
ated with a positive bacterial culture. This may represent
a true higher population prevalence in young male
patients to imported gastrointestinal bacterial infection
or may be related to a higher bacillary load in this popu-
lation. This may suggest that a lower threshold for pro-
viding empiric antimicrobial therapy in this group may
be advantageous depending on setting; this also high-
lights that this group may be worthy of further study in
prospective therapeutic trials.
Persistent abdominal symptoms are recognised com-
plications of travel related gastrointestinal disease and
management of these presentations may be challenging.
In our study a variety of demographic, travel, syndromic
and laboratory factors were found to influence the per-
sistence of symptoms at follow-up. Dysenteric diarrhoea,
peripheral leucocytosis at presentation and female sex all
predicted lack of resolution in our cohort. A travel
Table 2 Predictors of Aetiology of Imported Gastrointestinal Disease (Continued)
Resolution (N = 1235) Non-resolution (N = 215) Total (N = 1450) p value
Any Definitive Diagnosis 261 (21.1%) 40 (18.6%) 301 (20.8%) 0.399
Microbiological Diagnosis 214 (17.3%) 28 (13.0%) 242 (16.7%) 0.153
Bacterial 100 (8.1%) 11 (5.1%) 111 (7.7%) 0.118
Parasitic 119 (9.6%) 18 (8.4%) 137 (9.4%) 0.559
Diagnosis
Giardia intestinalis 78 (6.3%) 14 (6.5%) 92 (6.3%) 0.913
Entamoeba histolytica 6 (0.5%) 1 (0.5%) 7 (0.5%) 0.968
Blastocystis hominis 27 (2.2%) 2 (0.9%) 29 (2.0%) 0.225
Cryptosporidium parvum 13 (1.1%) 2 (0.9%) 15 (1.0%) 0.87
Cyclospora cayatanensis 6 (0.5%) 0 (0.0%) 6 (0.4%) 0.306
Campylobacter spp. 43 (3.5%) 4 (1.9%) 47 (3.2%) 0.215
Shigella spp. 22 (1.8%) 3 (1.4%) 25 (1.7%) 0.688
Salmonella spp. 35 (2.8%) 4 (1.9%) 39 (2.7%) 0.415
Plesiomonas shigelloides 5 (0.4%) 0 (0.0%) 5 (0.3%) 0.35
Table 3 Clinical Characteristics – Outcome at first follow-up
Odds Ratio for Parasitic Diagnosis 95% CI p value
Male Gender 1.07 0.74-1.53 0.721
Age >37 years 1.42 0.98-2.04 0.058
Travel to South Asia 2.55 1.75-3.70 <0.0001
Syndrome - Abdominal Pain and Bloating 0.68 0.36-1.20 0.214
Syndrome - Dysenteric Diarrhoea 0.22 0.066-0.53 <0.005
Syndrome - Other GI syndrome 0.70 0.16-2.00 0.556
Odds Ratio for Bacterial Diagnosis 95% CI p value
Male Gender 1.69 1.10-2.62 <0.05
Age <37 Years 2.04 1.25-3.43 <0.01
Travel to South Asia 0.47 0.24-0.83 <0.013
Travel to Southern Africa 0.11 0.006-0.52 <0.05
Stool Microscopy - White cells 3.52 2.09-5.86 <0.0001
CRP >5iu/dLa 4.68 2.91-7.72 <0.0001
aCases where CRP not performed removed from analysis
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history which included travel to North America was pre-
dictive of lack of resolution in this study; the most plaus-
ible explanation for this is a higher comparative
prevalence of non-infectious compared to infectious ae-
tiologies of gastrointestinal disease in high income set-
tings. Non-infectious gastrointestinal disease is known to
have a typically longer symptomatic course [21].
The strength of this study is that it may allow earlier
identification of those who would benefit most from fur-
ther investigations, such as abdominal imaging, endos-
copy, and specialist blood tests at the point of
presentation to healthcare providers upon return from
abroad. Practically these data suggest that patients with
dysenteric diarrhoea and a peripheral leucocytosis at as-
sessment should be prioritised for active follow up in
travel healthcare settings.
The retrospective nature of this study represents its
key limitation. Unfortunately, this means that the path-
ways for investigation and follow-up were not consistent
across all the cases included and led to our making sev-
eral assumptions regarding resolution. Key amongst
these was including those without follow-up data as
resolution which risks biasing our cohort of non-
resolving patients and highlighting confounders rather
than true predictors of non-resolution. However, we be-
lieve this is significantly mitigated by the fact that all pa-
tients had a planned clinician telephone call within a
week to inform patients of results which should have
acted as a “safety net” in these cases to minimise those
who had ongoing symptoms but no ongoing input from
our service. In addition to this, the perceived and actual
barriers to care in our setting were minimal as our clinic
is free of charge and open to all who meet travel criteria.
Finally, our cohort have already demonstrated a high de-
gree of healthcare seeking behaviour in the context of
their decision to self-refer to the clinic in the first in-
stance. These facts notwithstanding, we believe it is still
important to highlight this as a potential source of bias
within our data and should be considered in their inter-
pretation. Also, due to the breadth of our dataset and
the complexity of assessing of potentially multiple separ-
ate travel histories, our dataset does not include robust
data for time from travel to onset of symptoms or dur-
ation of symptoms. The link between shorter incubation
period and bacterial aetiology of imported diarrhoea is
well established and we hope that despite this limitation
we have potentially identified a number of other predict-
ive factors with respect to aetiology and outcome [21].
Similarly, our dataset is limited by our intentional omis-
sion of therapeutic data in our data collection strategy.
These data were not collected as we felt the complexity
and diversity of antimicrobial strategies which we would
find in our retrospective cohort of patients would preclude
any meaningful analysis as our group was intentionally
broad and the question of individual therapeutic efficacy
is not best addressed in a study such as this.
A further limitation of our study design was our classi-
fication of endpoints. To maximise our capture of on-
going symptoms in a complex syndromic population we
broadened our definition of non-resolution in our co-
hort. Practically, this means that “Non-resolution”
encompassed a variety of entities including partial symp-
tomatic resolution, symptomatic deterioration, and re-
lapse. All of these are recognised clinical outcomes in
the context of imported gastrointestinal disease. By
grouping of these different outcomes, we were able to
broaden our search for predictors of non-improvement
however this meant sacrificing resolution of patient level
symptom timelines. Further delineation of this would
best be performed in the context of a prospective study
with fixed timepoint symptomatic assessments, our data-
set did not allow such analysis. Additionally, we made
the decision to not restrict non-resolution to the original
group defining symptom (i.e. those with dysenteric diar-
rhoea would be classified as non-resolution in the pres-
ence of ongoing non-dysenteric diarrhoea at follow up).
This was intentional as a major non-infectious differen-
tial diagnosis of persistent diarrhoea is inflammatory
bowel disease and we therefore wished to capture these
patients in the “non-resolving” group.
Table 4 Predictors of Outcome of Imported Gastrointestinal Syndromes
Odds Ratio for Persistence of Symptoms 95% CI Pr(>|z|)
Female gender 1.45 1.06-1.99 <0.05
Age - 28-37 years 0.76 0.52-1.10 0.150
Age - >37 years 0.84 0.58-1.22 0.369
Travel to North America 3.61 1.57-7.9 <0.005
Syndrome - Abdominal Pain and Bloating 1.41 0.89-2.18 0.133
Syndrome - Dysenteric Diarrhoea 2.14 1.38-3.25 <0.0005
Syndrome - Other GI syndrome 0.58 0.14-1.67 0.380
Leucocytosisa 1.58 1.02-2.40 <0.05
aCases where peripheral white cell count not performed removed from analysis
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In conclusion, we have demonstrated a constellation
of factors which may predict both the aetiology and
prognosis of gastrointestinal disease in returning travel-
lers. We hope this will aid clinicians with initial assess-
ment of such patients and allow practical early triage of
patients for enhanced follow up.
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